Curi RMB Capital LLC Purchases New Holdings in Soleno Therapeutics, Inc. (NASDAQ:SLNO)

Curi RMB Capital LLC acquired a new stake in shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 4,000 shares of the company’s stock, valued at approximately $202,000.

Other hedge funds also recently added to or reduced their stakes in the company. Amalgamated Bank acquired a new position in Soleno Therapeutics in the 2nd quarter valued at $31,000. Victory Capital Management Inc. raised its position in Soleno Therapeutics by 26.3% during the second quarter. Victory Capital Management Inc. now owns 10,727 shares of the company’s stock worth $438,000 after acquiring an additional 2,236 shares during the last quarter. Sei Investments Co. lifted its stake in Soleno Therapeutics by 22.0% in the 1st quarter. Sei Investments Co. now owns 12,577 shares of the company’s stock valued at $538,000 after buying an additional 2,264 shares in the last quarter. California State Teachers Retirement System lifted its position in shares of Soleno Therapeutics by 33.8% in the first quarter. California State Teachers Retirement System now owns 13,780 shares of the company’s stock valued at $590,000 after acquiring an additional 3,481 shares in the last quarter. Finally, SG Americas Securities LLC acquired a new stake in shares of Soleno Therapeutics during the 2nd quarter worth about $569,000. 97.42% of the stock is owned by institutional investors and hedge funds.

Soleno Therapeutics Trading Down 4.2 %

Shares of SLNO stock opened at $51.80 on Friday. The firm has a fifty day simple moving average of $52.74 and a 200-day simple moving average of $47.98. The company has a market capitalization of $2.23 billion, a PE ratio of -15.60 and a beta of -1.44. Soleno Therapeutics, Inc. has a twelve month low of $22.20 and a twelve month high of $59.75.

Soleno Therapeutics (NASDAQ:SLNO) last announced its earnings results on Wednesday, November 6th. The company reported ($1.83) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.61) by ($1.22). Equities research analysts predict that Soleno Therapeutics, Inc. will post -3.76 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on SLNO shares. Cantor Fitzgerald restated an “overweight” rating and set a $67.00 price objective on shares of Soleno Therapeutics in a report on Friday, September 20th. HC Wainwright restated a “buy” rating and set a $70.00 price objective on shares of Soleno Therapeutics in a report on Monday, November 11th. Oppenheimer raised their price target on shares of Soleno Therapeutics from $65.00 to $73.00 and gave the company an “outperform” rating in a report on Monday, October 28th. Finally, Stifel Nicolaus upped their price target on shares of Soleno Therapeutics from $59.00 to $74.00 and gave the stock a “buy” rating in a research report on Tuesday, October 1st. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, Soleno Therapeutics has an average rating of “Buy” and a consensus target price of $69.86.

Insider Transactions at Soleno Therapeutics

In other news, insider Kristen Yen sold 5,270 shares of the company’s stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $47.58, for a total transaction of $250,746.60. Following the completion of the transaction, the insider now owns 90,008 shares in the company, valued at approximately $4,282,580.64. This represents a 5.53 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Vivo Opportunity, Llc sold 500,000 shares of the company’s stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $48.73, for a total transaction of $24,365,000.00. Following the completion of the transaction, the insider now owns 6,816,851 shares of the company’s stock, valued at approximately $332,185,149.23. This trade represents a 6.83 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 701,362 shares of company stock valued at $33,970,517. Insiders own 12.30% of the company’s stock.

About Soleno Therapeutics

Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.